Similarly, a significant reduction from baseline in DAS 28-C Reactive Protein (DAS28-CRP), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) was observed at different time points in RA patients who were switched from infliximab with methotrexate to tocilizumab (Anti-IL-6 drug) with or without methotrexate in Wakabayashi et al. study.12 In the SWITCH-RA prospective study, 604 patients received rituximab and 507 patients received an alternative anti-TNF-α drug after initial withdrawal of an anti-TNF-α drug. This evidence concerns the gene CRP and rheumatoid arthritis.